A recent preclinical study demonstrated that the inhibition of IL-17, using either a monoclonal antibody or a small-molecule IL-17 blocker, effectively elevated glucocorticoid sensitivity in steroid-resistant neutrophilic airway inflammation [85]. The gene discussed is IL17A; the disease is inflammatory response.